Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 10297 - 10304 of 12006 results

D'oh! OCR Confirms that Medical Records Should Not be Left in the Driveway
June 26, 2014| Blog| Viewpoint

To our US Readers: Your Privacy & Security Matters Blog Public Service for Thursday, June 26
June 26, 2014| Blog| Viewpoint

A Tale of Two Jurisdictions: Human Rights Laws in New York City and Tennessee Head in Opposite Directions
June 25, 2014| Blog| Viewpoint

Massachusetts High Court Permits Compelled Decryption of Seized Digital Evidence
June 25, 2014| Blog| Viewpoint

Puerto Rico Poised to Enact Bankruptcy-Like Legislation for Certain Revenue Bond Issuers
June 25, 2014| Blog| Viewpoint

OCR Confirms that Medical Records Should Not be Left in the Driveway
June 25, 2014| Blog| Viewpoint

ML Strategies Posts Weekly Health Care Update on June 23, 2014
June 25, 2014| Blog| Viewpoint
News & Press Releases
Mintz advised ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers, on a $75 million underwritten public offering of 2,482,692 shares of its common stock and pre-funded warrants to purchase up to 1,363,469 shares of its common stock. The common stock is listed on The Nasdaq Global Market under the symbol “AVBP.“
Mintz represented S2G Investments, a multi-stage investment firm focused on venture and growth-stage businesses across food & agriculture, oceans and energy, in its $40 million Series B financing of Sojo Industries, an industrial automation company that utilizes robotics, mobility, and software to deliver packaging and assembly solutions to the food and beverage industry.
Mintz advised Syntis Bio, a clinical-stage biopharmaceutical company revolutionizing oral therapies for obesity, diabetes, and rare diseases, on a $33 million oversubscribed Series A financing.
Events
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts

Mintz On Air: Practical Policies – An Abridged Guide to Crisis Management
July 1, 2025| Podcast|

Health Law Diagnosed: PBM Update Spring 2025
June 10, 2025| Podcast|
